Family Planning Knowledge, Attitudes, and Practices of Postpartum Malawian Women

Overview

The purpose of this study is to understand the family planning needs and practices of postpartum Malawian women, with a focus on long-acting reversible contraception (LARC). Hypotheses: 1. Postpartum women who are older, who have a history of unintended pregnancy, who do not desire another child within 2 years, and who were counseled about LARC during their pregnancy are more likely to have interest in using LARC. 2. Postpartum women who are older are more likely to be aware of LARC methods. 3. HIV+ postpartum Malawian women will have similar knowledge about LARC as postpartum Malawian women who are HIV-.

Full Title of Study: “Family Planning Knowledge, Attitudes, and Practices of HIV+ and HIV- Postpartum Malawian Women”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2014

Detailed Description

This study is a prospective cohort study of 630 postpartum Malawian women. Since our focus is on HIV+ women, HIV+ participants will be recruited in a 1:2 ratio, with a total of 210 HIV+ women and 420 HIV- women. We will recruit in the postpartum ward of Bwaila Maternity Hospital in Lilongwe, Malawi. Participants will complete a baseline survey about demographics, reproductive health history, and family planning knowledge, attitudes, and practices. At 3, 6, and 12 months postpartum, we will complete follow-up phone calls to determine what family planning methods they are using and if they encountered any barriers to receiving LARC if they had been interested in using them.

Arms, Groups and Cohorts

  • Postpartum Malawian women

Clinical Trial Outcome Measures

Primary Measures

  • Knowledge about the intrauterine device (IUD) and contraceptive implant
    • Time Frame: Upon enrollment
    • A 14-question test about the IUD and implant will be administered to all study participants upon enrollment.

Secondary Measures

  • Proportion of women using intrauterine device (IUD) and contraceptive implant
    • Time Frame: 3, 6, and 12 months postpartum
    • We will compare the proportions of HIV+ and HIV- women who are using the IUD and implant at 3, 6, and 12 months postpartum.
  • Barriers to receiving intrauterine device (IUD) and contraceptive implant
    • Time Frame: Up to 12 months postpartum
    • Descriptive statistics will be used to analyze the reasons given for not receiving the IUD or implant at 3, 5, and 12 months postpartum if a woman had wanted to use it.

Participating in This Clinical Trial

Inclusion Criteria

1. Admission to the postpartum ward at Bwaila Maternity Hospital 2. Live birth ≥28 weeks gestational age within past 4 weeks 3. Fluent in English or Chichewa 4. Age 18-45 years 5. Access to a working phone number 6. Willingness to be contacted by phone for up to one year postpartum Exclusion Criteria:

1. History of female sterilization via tubal ligation or hysterectomy 2. Prisoner 3. History of mental disability 4. Serious illness that would prevent participation in the opinion of the Principal Investigator

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of North Carolina, Chapel Hill
  • Collaborator
    • Fogarty International Center of the National Institute of Health
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jennifer Tang, MD, MSCR, Research Assistant Professor – University of North Carolina, Chapel Hill
  • Overall Official(s)
    • Jennifer Tang, MD, MSCR, Principal Investigator, University of North Carolina, Chapel Hill
    • Mina Hosseinipour, MD, MPH, Study Director, University of North Carolina, Chapel Hill

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.